Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs; Announces Second Quarter 2007 Financial Results

Hollis-Eden Pharmaceuticals, Inc., the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, reported on its progress and outlook for the company’s drug development programs in the areas of metabolic disorders, inflammatory conditions and cancer, and announced financial results for the second quarter of 2007.
Hollis-Eden Pharmaceuticals